SUSMED,Inc. (JP:4263)
:4263
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥413.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥14.88B
Enterprise Value¥12.65B
Total Cash (Recent Filing)¥4.40B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet (no Debt)Zero reported debt and roughly ¥4.37B of equity materially lower financial risk and give management time and flexibility to fund operations or invest in product development. This structural buffer supports execution while the company seeks to cure operating losses without immediate refinancing pressure.
Exceptionally High Gross Margins (~97%)Sustained ~97% gross margins indicate software- or asset-light unit economics and strong pricing power in core offerings. These margins create scope for operating leverage: if revenue growth is sustained, incremental revenue can flow quickly to the operating line, improving path to profitability.
Revenue Growth Resumed In 2025A return to positive top-line growth signals improving market traction after a prior decline. Coupled with very high gross margins, sustained revenue expansion would enable scalable margin improvement and justify continued investment in distribution and product development over the medium term.
Bears Say
Worsening Cash Burn And Negative FCFIncreasing negative operating and free cash flows reduce runway and force reliance on external financing or equity dilution to fund operations. Over the next 2–6 months, sustained cash burn can constrain strategic choices, slow go-to-market activity, and pressure the balance sheet despite current equity buffers.
Deep And Persistent Net LossesVery large negative net margins show operating costs and overhead still far exceed revenues. Even with margin improvement, the scale of losses implies structural cost or monetization issues; failure to materially narrow losses risks prolonged unprofitability and undermines long-term capital efficiency.
Erosion Of Equity And Negative ROEDeclining book equity and negative ROE reflect capital erosion from sustained losses. This structural deterioration reduces shareholder value, limits internal funding for growth, and may worsen financing terms over time, increasing the likelihood of dilution or constrained investment capacity.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥413.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥14.88B.
When is SUSMED,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SUSMED,Inc.’s earnings last quarter?
Currently, no data Available
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED, Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.